# A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis

> **NCT03798366** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 33 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** GLPG1690
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03798366
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-06-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798366, "A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03798366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*